Patrys antibody awarded orphan drug status in US
07 November, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) now has orphan drug status for antibody PAT-SM6 in multiple myeloma covering the US as well as the EU.
Government vetoes cap on self-education expenses
07 November, 2013The federal government will not go ahead with a proposed cap on self-education expenses.
NHMRC recognises researchers' hard work
04 November, 2013The NHMRC has recognised a human molecular geneticist and an IVF researcher with the respective NHMRC Outstanding Contribution Award and the NHMRC Ethics Award.
Prana shares surge on Alzheimer's study results
01 November, 2013 by Dylan Bushell-EmblingShares in Prana Biotechnology (ASX:PBT) climbed 43% after a scientific paper detailed how Alzheimer's drug candidate PBT2 reversed cognitive and memory loss in old mice.
Alchemia gets $8.8m R&D tax rebate for FY13
30 October, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has received an $8.8m R&D tax incentive windfall, as it benefited from a finding that it can apply for a rebate on some research conducted overseas.
Bridging the gap between health and wellness
30 October, 2013 by Susan WilliamsonFiona Wood reflects on her career choice as a plastic surgeon, combining this with clinical research and the challenges involved in improving clinical outcomes of burns patients.
Celebrating 20 years of medical research policy advocacy
28 October, 2013 by Susan WilliamsonThe Association of Australian Medical Research Institutes celebrates its 20th birthday this week.
Starpharma's docetaxel formula tackles neutropenia
25 October, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has published a second set of preclinical data suggesting that cancer drugs produced with its dendrimer platform can eliminate bone marrow toxicity neutropenia.
Disturbing infection trends
25 October, 2013Annual survey shows rates of chlamydia, gonorrhoea and syphilis infection are on the increase.
Mesoblast forms three-way cancer R&D tie-up
24 October, 2013 by Dylan Bushell-EmblingMesoblast (ASX:MSB), Ziopharm Oncology and Intrexon have teamed up to develop a new class of cell-based cancer treatments, with an initial focus on lung cancer.
NHMRC 2013 grants announced
24 October, 2013 by Susan WIlliamsonThe outcomes of the NHMRC 2013 grant round have been announced.
Imugene steps in to buy Biolife Science
23 October, 2013 by Dylan Bushell-EmblingImugene (ASX:IMU) has agreed to buy Biolife Science, the cancer immunotherapy company that called off a backdoor ASX listing and capital raising earlier this year.
New Zealand's Innate moves to Australia
16 October, 2013 by Dylan Bushell-EmblingInnate Immunotherapeutics has moved its base from Auckland to Sydney as it prepares for Australian phase IIb trials of SPMS treatment candidate MIS416.
Ramaciotti Awards and a new human systems biology centre
16 October, 2013The 2013 recipients of the biennial Ramaciotti Awards for biomedical research have been announced.
Translational Research Institute officially opened
15 October, 2013Brisbane's new biomedical research institute, Translational Research Institute, has been officially opened by the Governor-General, Her Excellency the Honourable Quentin Bryce.
